[Foetal therapy for Down syndrome: a pro-active ethical reflection].

Area of Science:

• Medical Ethics
• Genetics
• Prenatal Diagnostics

Background:

• Prenatal screening for Down syndrome traditionally focuses on pregnancy continuation decisions.
• Non-invasive prenatal testing (NIPT) opens possibilities for novel interventions.
• Fetal neurocognitive therapy for Down syndrome (FTDS) is a potential future application.

Purpose of the Study:

• To proactively explore the ethical considerations of FTDS.
• To assess the ethical permissibility of clinical trials for FTDS.
• To examine the implications of effective FTDS for current prenatal screening practices.

Main Methods:

• Ethical analysis based on the social model of disability.
• Review of arguments concerning autonomy, wellbeing, and justice.
• Discussion of prerequisites for ethical clinical trials.

Main Results:

• No convincing a priori ethical objections to FTDS were identified based on the social model of disability.
• Ethical principles of autonomy, wellbeing, and justice appear to support FTDS in principle.
• Further scrutiny is needed regarding clinical trial conditions and screening implications.

Conclusions:

• FTDS presents a potential paradigm shift in Down syndrome care, moving beyond screening to intervention.
• Ethical frameworks generally support the exploration of FTDS, pending rigorous clinical trial evaluation.
• The advent of effective FTDS necessitates a re-evaluation of the goals and practices of prenatal screening.